GYRE
Gyre Therapeutics Inc.
6.80$
-4.0%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1,902.0% | -1,092.5% | -4,629.6% | -1,958.7% | -475,883.3% | – | -262.8% | -1,141.4% | 10.4% | 22.8% | -3.4% | 0.9% | |
| 19.4% | 26.9% | 97.5% | 17.0% | 2,483.3% | – | 0.7% | 4.0% | 1.1% | 1.0% | 1.5% | 2.1% | |
| 191.5% | 18.6% | 159.1% | 84.8% | 43,433.3% | – | 17.3% | 46.4% | 13.1% | 6.4% | 0.8% | 6.1% | |
| -351.2% | -357.7% | 209.5% | 55.7% | -22,816.7% | – | -12.3% | 6.6% | -7.6% | 6.6% | -14.8% | -13.3% | |
| 0.2% | 15.5% | 117.3% | 2.3% | 6,266.7% | – | 1.3% | 11.4% | 4.9% | 7.6% | 3.0% | 1.0% | |
| 1,867.4% | 2,134.7% | -327.8% | -1,105.3% | -1,188,683.3% | – | 46.1% | 656.7% | -13.5% | -17.4% | -18.8% | -0.4% | |
| – | – | – | 388.1% | – | – | – | 0.0% | 44.0% | – | – | – | |
| – | -4.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -91.3% | -0.5% | – | – | – | |
| 276.2% | 532.2% | 237.6% | 3,477.4% | 1,855,533.3% | – | 288.2% | 675.3% | -44.0% | 2.2% | 2.0% | 20.9% | |
| 107.3% | 1,574.4% | -4,719.8% | 413.4% | 190,966.7% | – | 71.6% | 190.6% | -4.9% | 7.3% | -20.5% | 21.7% | |
| -1,902.2% | -1,108.0% | -4,746.9% | -1,961.0% | -482,150.0% | – | -264.1% | -1,152.8% | 5.6% | 15.3% | -6.4% | -0.2% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.